Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 16/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP5 | P51878 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5527526 | 0.98 | TACR1 (0.43) | TACR1METGPBAR1USP2CYP1A2 | |
| SCHEMBL5530970 | 0.96 | TACR1 (0.44) | TACR1METGPBAR1CASP1CASP5 | |
| SCHEMBL5533230 | 0.93 | TACR1 (0.44) | TACR1METGPBAR1USP2CYP1A2 | |
| SCHEMBL5531994 | 0.91 | MET (0.46) | TACR1METCASP1CASP5USP2 | |
| SCHEMBL5526922 | 0.89 | MET (0.48) | TACR1METCASP1CASP5USP2 | |
| SCHEMBL5534321 | 0.88 | NPC1 (0.38) | TACR1METUSP2CYP1A2CYP2C19 | |
| SCHEMBL13891620 | 0.88 | TACR1 (0.43) | TACR1METCASP1CASP5USP2 | |
| SCHEMBL5532515 | 0.88 | MET (0.39) | TACR1METCASP1CASP5USP2 | |
| SCHEMBL5534340 | 0.86 | GPBAR1 (0.47) | TACR1GPBAR1CASP1CASP5CYP1A2 | |
| SCHEMBL6093692 | 0.86 | TACR1 (0.39) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1489083-B1 | FUSED BICYCLIC PYRIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | KYORIN SEIYAKU KK (JP) | 2007-06-06 | — | — | EP | disclosed |
| US-7026309-B2 | Fused bicyclic pyridine derivative as tachykinin receptor antagonist | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-04-11 | — | — | US | disclosed |
| US-20050101591-A1 | Fused bicyclic pyridine derivative as tachykinin receptor antagonist | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1489083-A1 | FUSED BICYCLIC PYRIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101591-A1 | Fused bicyclic pyridine derivative as tachykinin receptor antagonist | BDKRB1, BDKRB2, NPY1R | TACR1 4/4885MET 1249/4885GPBAR1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.